36 FavaudonVCMonceauLPouzouletVSayarathFFouilladeMPouponCet al
Selective inhibition of hypoxia-inducible factor 1alpha ameliorates adipose tissue dysfunction

Disclosures: Christine Espiritu: Nothing to Disclose, Andrzej Ardzinski: Arbutus Biopharma: Employee, Holly Micolochick Steuer: Nothing to Disclose, Varun Sharma: Nothing to Disclose, Kevin Gray: Nothing to Disclose, Deana Antoniello: Nothing to Disclose, Timothy Eley: Arbutus Biopharma: Employee, Arbutus Biopharma: Stock - publicly traded company, Karen Sims: Nothing to Disclose, Andrea Cuconati: Nothing to Disclose, Angela Lam: Nothing to Disclose, Michael Sofia: Arbutus Biopharma: Employee, Emily Thi: Arbutus Biopharma: Employee and holds shares in Arbutus Biopharma, Arbutus Biopharma: Employee and holds shares in Arbutus Biopharma 435 IMPACT OF METABOLIC DISEASE ON TREATMENT RESPONSE IN CHRONIC HEPATITIS B PATIENTS WITH NUCLEOS(T)IDE ANALOGUES THERAPY: A MULTICENTER REAL-B STUDY Rui Huang 1 Dae Won Jun 2 Hidenori Toyoda 3 Yao-Chun Hsu 4 Huy Trinh 5 Akito Nozaki 6 Toru Ishikawa 7 Tsunamasa Watanabe 8 Haruki Uojima 9 Daniel Huang 10 Takashi Honda 11 Yasuhito Tanaka 12 Philip Vutien 13 Sebastin Marciano 14 Hiroshi Abe 15 Masaru Enomoto 16 Masanori Atsukawa 17 Hirokazu Takahashi 18 Kunihiko Tsuji 19 Ei Itobayashi 20 Koichi Takaguchi 21 Pei-Chien Tsai 22 Chia-Yen Dai 22 Jee-Fu Huang 22 Chung-Feng Huang 22 Ming-Lun Yeh 22 Eileen Yoon 23 Sung Eun Kim 24 Sang Bong Ahn 25 Gi-Ae Kim 26 JangHan Jung 27 Soung Won Jeong 28 Hyun Woo Oh 29 Cheng-Hao Tseng 4 Masatoshi Ishigami 11 Angela Chau 30 Tiffany Hsiao 30 Mayumi Maeda 30 Satoshi Yasuda 3 Makoto Chuma 31 Takanori Ito 11 Keigo Kawashima 12 Joann Kimiko Liu 30 Adrian Gadano 14 Ritsuzo Kozuka 16 Norio Itokawa 17 Kaori Inoue 18 Tomonori Senoh 21 Jie Li 32 Wan Long Chuang 33 Ramsey Cheung 34 Chao Wu 32 Ming-Lung Yu 33 Mindie Nguyen 30 , 1 Stanford University Medical Center

Side Effects Generally well tolerated
DOTS comprise of four antibiotics: isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (ETH) for two months (initial phase) followed by INH, and RIF for four months (continuation phase) (Lagman et al., 2015)
2017;14(Supplement_1):S30-s9